PCSK9 Inhibition for Therapeutic Decision-Making: Assessing the Value.
- 2020
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
English
0735-1097
10.1016/j.jacc.2020.03.037 [doi] S0735-1097(20)34648-9 [pii]
*Acute Coronary Syndrome
*Proprotein Convertase 9
Antibodies, Monoclonal, Humanized
Cost-Benefit Analysis
Humans
MedStar Heart & Vascular Institute
Editorial